SARS-CoV-2 spike protein (RBD) neutralizing (C-A11) rabbit mAb

Catalog #: 2536
Select Your Size Price
200 uL (0.5 mg/mL)(2536) $475.00
From $475.00

Need to make a custom order?

Contact us


20 μL is enough antibody for at least 20 Western blots.

Product Overview


This antibody recognizes the SARS-CoV-2 spike protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2. The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, and O-acetylated sialic acid. The spike protein is essential for both host specificity and viral infectivity. The term ‘peplomer’ is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It’s been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the spike protein are summarized as: mediates receptor binding and membrane fusion, defines the range of the hosts and specificity of the virus; main component to bind with the neutralizing antibody; key target for vaccine design; and can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.

Product Details

Product Details
Specification Description
Special Notice Avoid multiple freeze and thaw cycles.
Applications Functional Assay
Clone CoV2-CA11
Format Unconjugated
Validated Reactivity Other
Cross Reactivity U.K coronavirus variant B.1.1.7, South Africa variant B.1.351
Detection Anti-Rabbit IgG
Clonality Monoclonal
Immunogen recombinant protein (RBD)
Formulation 1X PBS, 50% Glycerol
Isotype Rabbit IgGk
Preparation Protein A
Recommended Usage This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2. Can be paired with other antibody for detection in sandwich ELISA format.
Storage -20ºC
Pseudonyms Spike protein S1, Spike protein S2, RBD domain, Binding to ACE-2 receptor, SARS-CoV-2 variants, U.K variant B.1.1.7, South Africa variant B.1.351
Uniprot ID P0DTC2


Cell Culture Products
Flow cytometry neutralizing assay: C-A11 displayed dose dependent blocking of spike proteins (wild type and UK variant) to ACE2 expressing cells.
Cell Culture Products
Affinity assessment of SARS-CoV-2 C-A11 IgG to wild type and B.1.1.7 (UK) S1+S2 trimers. C-A11 possesses very low (pM) KD affinity to both variants.
Cell Culture Products
Flow cytomery neutralizing assay of C-A11 (plotted graphs): ACE2 transfected cells were incubated with biotinylated spike protein (0.5 ug/mL) in the presence or absence of antibody. Binding of spike protein was detected with DyLight488 conjugated StreptAv
Cell Culture Products
Binding of C-A11 to SARS-CoV-2 variants (UK and South Africa): C-A11 shows good cross reactivity to both variants B.1.1.7 (UK) and B.1.351 (S. Africa).

Associated Products